CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
51 hedge funds and large institutions have $36.4M invested in CASI Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 4 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 50 → 51 (+1)
0.08% less ownership
Funds ownership: 1.22% → 1.14% (-0.08%)
2% less capital invested
Capital invested by funds: $37.3M → $36.4M (-$895K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
+$558K |
| 2 |
BlackRock
New York
|
+$397K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$171K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$100K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$89.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSC
Wellington Shields & Co
New York
|
-$3.6M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$127K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$122K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$79.7K |
| 5 |
HF
HRT Financial
New York
|
-$53K |
CASI Hedge Fund Activity: Q3 2019 in Review
51 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2019, worth a combined $36.4M — down 2.4% from $37.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CASI positions and 4 closed out — a net gain of 1 holder — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Shields Capital Management, adding an estimated $558K. The largest seller was Wellington Shields & Co, exiting entirely with an estimated $3.6M sold.
- 51 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2019, up from 50 in Q2 2019.
- Funds reported $36.4M of CASI Pharmaceuticals stock for Q3 2019, down 2.4% quarter-over-quarter.
- 5 funds opened new CASI Pharmaceuticals positions in Q3 2019 and 4 closed out, a net change of +1 holder.
- The largest CASI Pharmaceuticals buyer in Q3 2019 was Wellington Shields Capital Management, an estimated $558K added.
- The largest CASI Pharmaceuticals seller in Q3 2019 was Wellington Shields & Co, an estimated $3.6M sold.
Based on aggregated 13F filings for Q3 2019.